ZHX2 and breast carcinoma: We first examined the interaction of ZHX2 and p65 in breast cancer by endogenous IP with ZHX2 or p65 antibody in two TNBC cells (MDA-MB-231 and 468) (Figure 4—figure supplement 1A, B), we did not find consistent and robust binding between ZHX2 and p65 as we observed in ccRCC.